194 related articles for article (PubMed ID: 33194568)
1. Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database.
Cheng R; Kong X; Wang X; Fang Y; Wang J
Front Oncol; 2020; 10():1583. PubMed ID: 33194568
[No Abstract] [Full Text] [Related]
2. The Level of Agreement Among Medical Oncologists on Adjuvant Chemotherapy Decision for Breast Cancer in Pre and Post-Oncotype DX Settings.
Alkushi A; Omair A; Masuadi E; Alamri G; Abusanad A; Abdelhafiez N; Mohamed AE; Abulkhair O
Cureus; 2021 Feb; 13(2):e13298. PubMed ID: 33738150
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
Roberts MC; Miller DP; Shak S; Petkov VI
Breast Cancer Res Treat; 2017 Jun; 163(2):303-310. PubMed ID: 28243896
[TBL] [Abstract][Full Text] [Related]
4. Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
Ibraheem AF; Press DJ; Olopade OI; Huo D
Cancer; 2019 Jan; 125(2):213-222. PubMed ID: 30387876
[TBL] [Abstract][Full Text] [Related]
5. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
[TBL] [Abstract][Full Text] [Related]
6. The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center.
Thibodeau S; Voutsadakis IA
Eur J Breast Health; 2019 Jul; 15(3):163-170. PubMed ID: 31312792
[TBL] [Abstract][Full Text] [Related]
7. Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey.
Ünal Ç; Özmen T; Ordu Ç; Pilanci KN; İlgün AS; Gökmen E; Almuradova E; Özdoğan M; Güler N; Uras C; Kara H; Demircan O; Işık S; Alço G; Saip P; Aydın E; Duymaz T; Çelebi F; Yararbaş K; Soybir G; Ozmen V
Front Oncol; 2023; 13():1151733. PubMed ID: 37448522
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with chemotherapy benefit in breast cancer patients with midrange Oncotype DX breast recurrence scores.
Cheng R; Wang Z; Kong X; Wang J; Fang Y; Qi L
Cancer Lett; 2021 Apr; 503():213-219. PubMed ID: 33485948
[TBL] [Abstract][Full Text] [Related]
9. Predicting Chemotherapy Benefit across Different Races in Early-Stage Breast Cancer Patients Using the Oncotype DX Score.
Shaw VR; Amos CI; Cheng C
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370827
[TBL] [Abstract][Full Text] [Related]
10. Can We Forgo Sentinel Lymph Node Biopsy in Women Aged ≥ 50 Years with Early-Stage Hormone-Receptor-Positive HER2-Negative Special Histologic Subtype Breast Cancer?
Knape N; Park JH; Agala CB; Spanheimer P; Morrow M; Downs-Canner S; Baldwin XL
Ann Surg Oncol; 2023 Feb; 30(2):1042-1050. PubMed ID: 36217063
[TBL] [Abstract][Full Text] [Related]
11. Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.
Kwon MJ; Lee JE; Jeong J; Woo SU; Han J; Kang BI; Kim JE; Moon Y; Lee SB; Lee S; Choi YL; Kwon Y; Song K; Gong G; Shin YK
Front Oncol; 2019; 9():667. PubMed ID: 31404265
[No Abstract] [Full Text] [Related]
12. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S
Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456
[TBL] [Abstract][Full Text] [Related]
13. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
[TBL] [Abstract][Full Text] [Related]
14. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
Zhang L; Hsieh MC; Petkov V; Yu Q; Chiu YW; Wu XC
Breast Cancer Res Treat; 2020 Apr; 180(2):491-501. PubMed ID: 32060781
[TBL] [Abstract][Full Text] [Related]
15. The Oncotype DX Recurrence Score's Impact on the Management of Oestrogen-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Low-Burden Axillary Status Breast Cancer (REHAB Study): Results of a Single Centre.
Saad Abdalla Al-Zawi A; Yin SL; Mahmood B; Jalil A; Aladili Z
Cureus; 2022 Jul; 14(7):e27341. PubMed ID: 36042999
[TBL] [Abstract][Full Text] [Related]
16. Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center.
Losk K; Freedman RA; Laws A; Kantor O; Mittendorf EA; Tan-Wasielewski Z; Trippa L; Lin NU; Winer EP; King TA
Breast Cancer Res Treat; 2021 Jan; 185(1):215-227. PubMed ID: 32939592
[TBL] [Abstract][Full Text] [Related]
17. The Prognostic Significance of the Oncotype DX Recurrence Score in T
Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
[TBL] [Abstract][Full Text] [Related]
18. Application of a 21-Gene Recurrence Score in a Swiss Single-Center Breast Cancer Population: A Comparative Analysis of Treatment Administration before and after TAILORx.
Chiru ED; Oseledchyk A; Schoetzau A; Kurzeder C; Mosimann R; Vetter M; Grašič Kuhar C
Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201405
[TBL] [Abstract][Full Text] [Related]
19. Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2-, node-positive early breast cancer.
Crager M; Wijayawardana SR; Gruver AM; Blacklock A; Russell C; Baehner FL; Sapunar F
Breast Cancer Res; 2022 Nov; 24(1):74. PubMed ID: 36320066
[TBL] [Abstract][Full Text] [Related]
20. 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer.
Geyer CE; Tang G; Mamounas EP; Rastogi P; Paik S; Shak S; Baehner FL; Crager M; Wickerham DL; Costantino JP; Wolmark N
NPJ Breast Cancer; 2018; 4():37. PubMed ID: 30456299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
